Paper Details

  1. Home
  2. Paper Details

Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.

Author: Abe-TakahashiYui, ChibaHiroki, HiguchiMadoka, KittaTakeya, KonMasafumi, KusakabeNaohisa, OuchiMifuka, ShinoharaNobuo, TogoMio, TsukiyamaMayuko

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Overactive bladder (OAB) is a common condition that can cause urinary problems. Antimuscarinic drugs are commonly used to treat OAB, but they can cause side effects. Vibegron is a new drug that targets a different protein, which may lead to fewer side effects. However, it has not yet been studied in children.
Paper Details　
Original Abstract of the Article :
Idiopathic overactive bladder (OAB) is defined as an urgency symptom with or without urge incontinence, which is not due to known neurological abnormalities. Since children present with variable symptoms, pediatric nonneurogenic idiopathic OAB is a condition that is difficult to diagnose and treat. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jpurol.2022.07.012

データ提供：米国国立医学図書館（NLM）

Vibegron for Overactive Bladder in Children and Adolescents

This study explores the potential of vibegron, a β3-adrenergic receptor agonist, in treating overactive bladder (OAB) in children and adolescents. While vibegron has been studied in adults, its efficacy in the pediatric population remains largely unknown. The study highlights the challenges of diagnosing and treating OAB in children and emphasizes the need for further research to evaluate the safety and efficacy of vibegron in this age group.

Expanding Treatment Options for Pediatric OAB

The study's findings underscore the need for expanding treatment options for pediatric OAB, a condition that can significantly impact quality of life. While antimuscarinic therapies remain the mainstay of treatment, their limitations in terms of side effects and efficacy warrant exploring alternative approaches, such as vibegron. Further research is essential to evaluate the potential benefits and risks of vibegron in children and adolescents.

Navigating the Pediatric Urinary Tract

The study's findings are like navigating the intricate pathways of the pediatric urinary tract, where understanding the unique needs of this population is crucial for effective treatment. As Dr. Camel, I am always fascinated by the complexities of childhood health and the ongoing search for safer and more effective therapies to address conditions like OAB.
Date :
  1. Date Completed 2022-12-16
  2. Date Revised 2022-12-22
Further Info :

Pubmed ID

35965225

DOI: Digital Object Identifier

10.1016/j.jpurol.2022.07.012

Related Literature

Article Analysis
・Effects of vibegron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.